Global Ceftriaxone Sodium for Pulmonary Diseases Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Ceftriaxone Sodium for Pulmonary Diseases Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Ceftriaxone injection is used to treat certain infections caused by bacteria such as gonorrhea (a sexually transmitted disease), pelvic inflammatory disease (infection of the female reproductive organs that may cause infertility), meningitis (infection of the membranes that surround the brain and spinal cord), and infections of the lungs, ears, skin, urinary tract, blood, bones, joints, and abdomen. Ceftriaxone injection is also sometimes given before certain types of surgery to prevent infections that may develop after the operation. Ceftriaxone injection is in a class of medications called cephalosporin antibiotics. It works by killing bacteria. Antibiotics such as ceftriaxone injection will not work for colds, flu, or other viral infections. Using antibiotics when they are not needed increases patient's risk of getting an infection later that resists antibiotic treatment.

Injecting ceftriaxone sodium may cause some sequelae, such as pain, tenderness, hardening or warming of the place where ceftriaxone sodium is injected; pale skin, weakness or shortness of breath during exercise; diarrhea, etc.

Market Overview:

The latest research study on the global Ceftriaxone Sodium for Pulmonary Diseases market finds that the global Ceftriaxone Sodium for Pulmonary Diseases market reached a value of USD 596.81 million in 2022. It’s expected that the market will achieve USD 694.25 million by 2028, exhibiting a CAGR of 2.55% during the forecast period.

Market Challenges

With the development of the economy, the level of per capita income continues to increase. People's consumption levels are also rising. What followed is that people pay more and more attention to the medical industry. In addition, economic development has also brought about technological progress, and industrial production methods tend to be intelligent and industrialized. This has brought opportunities and challenges to the ceftriaxone sodium industry.

Since antibiotics were discovered and used in large quantities, there have been more and more varieties of antibiotics. Including natural antibiotics and synthetic ones. Today, ceftriaxone sodium is one of the most widely used antibiotics on the market. However, in recent years, new antibiotics have appeared, such as the fourth and fifth generation antibiotics. Such as Cefpirome, Ceftorol and so on. This is a challenge for ceftriaxone sodium.

The main raw materials of ceftriaxone sodium for lung diseases are triazine ring and 7-ACA. Other raw materials include solvents and catalysts. Crude oil prices have fluctuated greatly over the years, which has led to fluctuations in the prices of many organic substances that are produced from oil. In addition, the prevalence of COVID-19 has also disrupted the production chain and affected the prices of raw materials. Therefore, the price fluctuation of raw materials is one of the biggest problems that ceftriaxone sodium manufacturers need to solve. The price fluctuation of raw materials is a big challenge for the ceftriaxone sodium industry.

Region Overview:

From 2023-2028, Asia Pacific is estimated to witness robust growth prospects.

Company Overview:

Pfizer is one of the major players operating in the Ceftriaxone Sodium for Pulmonary Diseases market, holding a share of 2.77% in 2021.

Pfizer Inc. is an American multinational pharmaceutical corporation headquartered on 42nd Street in Manhattan, New York City. Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than US$1 billion in annual revenues.

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalized healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines.

Segmentation Overview:

Among different product types, Powder for Solution for Injection segment is anticipated to contribute the largest market share in 2028.

Application Overview:

By application, the Tracheitis segment occupied the biggest share from 2018 to 2022.

Key Companies in the global Ceftriaxone Sodium for Pulmonary Diseases market covered in Chapter 3:

Taiwan Panbiotic Laboratories
Youcare Pharmaceutical
Shandong Luoxin Pharmaceutical
Lupin Pharmaceuticals
Zhejiang Yongning Pharmaceutical
Kelun Group
Pfizer
Roche
Novartis
Shandong Runze Pharmaceutical
Qilu Pharmaceutical
Yatai Pharma
Tonglian Group
Fresenius

In Chapter 4 and Chapter 14.2, on the basis of types, the Ceftriaxone Sodium for Pulmonary Diseases market from 2018 to 2029 is primarily split into:

Powder for Solution for Injection
Injections

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Ceftriaxone Sodium for Pulmonary Diseases market from 2018 to 2029 covers:

Pneumonia
Tracheitis

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)